It is important that you discuss with your physician / healthcare professional the best choices for you; their advice always takes priority over any guidance provided by Solarc.
“I would love to take this opportunity to thank you very much for this product I have purchased, I suffer from severe psoriasis and my doctor has prescribed me many different creams, oils, oral medication all to no avail.
Since I’ve had these lights it’s been amazing!! I no longer am embarrassed of this condition, I wear shorts comfortably and no more irritated itchy skin, I sleep without scratching all through the night. I use it 2-3 days a week for 2 minutes (rotating myself) so a total of 8 minutes per treatment!
I have sent a before and now picture of my elbow… And this is not a year yet! Very impressed and I have since referred your company to friends who suffer from skin conditions. I had no financial aid from insurance… I tried but I was denied
I’m still very happy cuz it works!! Thanks again!”
Debbie, MB, Canada
References & Links:
- While it is physicians that decide which medical treatments ought to be used, if a healthcare system is paying, it is the government that establishes the “formulary” that dictates which drugs and medical devices get used and when. For example in Ontario, Canada; the 2015 Ontario Ministry of Health formulary for the biologic drug Adalimumab (Humira®) states that it is: “For the treatment of severe plaque psoriasis 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies: 6 month trial of at least 3 topical agents including Vitamin D analogues and steroids; 12 week trial of phototherapy (unless not accessible); 6 month trial of at least 2 systemic, oral agents… methotrexate, acitretin, cyclosporine…” This can be interpreted as the government’s acknowledgement that phototherapy is a “standard therapy”, as it is proven to be both economically and medically effective. Indeed, across Canada there are about 100 publicly funded phototherapy clinics and countless home phototherapy devices.
- Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study) Koek M.B., Buskens E., Van Weelden H., Steegmans P.H., Bruijnzeel-Koomen C.A., Sigurdsson V.
- Are narrowband ultraviolet B home units a viable option for continuous or maintenance therapy of photoresponsive diseases? Haykal K.A., DesGroseilliers J.P.
- A review of phototherapy protocols for psoriasis treatment. The purpose of this review is to provide some practical guidance to general dermatologists and residents on the specifics of using phototherapy, which, despite its decreasing use, remains one of our most safe and effective treatment strategies for psoriasis care. Lapolla W., Yentzer B.A., Bagel J., Halvorson C.R., Feldman S.R.
- Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dosephototherapy. Maiorino A., De Simone C., Perino F., Caldarola G., Peris K.
- Pregnancy and Nursing guideline National Psoriasis Foundation
- From a Humira® TV commercial aired in Barrie, Canada on the night of Jan09-2015: “Humira can lower your ability to fight infections including tuberculosis. Serious, sometimes fatal infections and cancers including lymphoma, have happened; as have blood, liver, and nervous system problems, serious allergic reactions, and new or worsening heart failure.”
- Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis, An Evidence-Based Analysis, Health Quality Ontario
Humira is a registered trademark of AbbVie Inc.
Otezla is a registered trademark of Celgene Corporation
Soriatane is a registered trademark of Stiefel Laboratories, Inc.
Stelara is a registered trademark of Janssen Biotech, Inc.
Dovonex, Dovobet and Taclonex are registered trademarks of LEO Laboratories Ltd.